Haleon to increase stake in
27 September 2024: Haleon plc ("Haleon") (LSE/NYSE: HLN) today announces that it has entered into an agreement to acquire an additional 33%1 equity interest in Tianjin TSKF Pharmaceutical Co. Ltd ("TSKF"), its joint venture in
TSKF accounted for c. 40% of Haleon's
In addition, Haleon and DRTG have agreed, effective from closing of the acquisition, that Haleon would have an option to acquire and DRTG an option to sell the remaining 12% shareholding in TSKF.
Brian McNamara, Chief Executive Officer of Haleon commented: "
Notes
1. This transaction consists of a simultaneous and inter-conditional purchase of the entire 20% equity interest in TSKF held by TPG and a 13% equity interest in TSKF held by DRTG.
Amanda Mellor
Company Secretary
Enquiries
Investors |
Media
|
||
Sonya Ghobrial |
+44 7392 784784 |
Zoë Bird |
+44 7736 746167 |
Rakesh Patel |
+44 7552 484646 |
Gemma Thomas |
+44 7985 175048 |
Emma White |
+44 7823 523562 |
|
|
Email: investor-relations@haleon.com |
Email: corporate.media@haleon.com |
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information please visit www.haleon.com
About TSKF
Founded in 1984, TSKF is a joint venture of Haleon, TPG and DRTG in
About TPG
TPG is a large-scale pharmaceutical group based in
About DRTG
DRTG (SHSE: 600329 / SGX: T14) is the core pharmaceutical manufacturing arm of TPG. DRTG is engaged in the research, development and manufacturing of Chinese herbal medicines, proprietary Chinese medicines, western medicine, and other products primarily in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.